GLP1R and type 2 diabetes mellitus: Sodium–glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have individually been shown to reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease (ASCVD) or multiple CVD risk factors [1, 2].